UNSPSC 51131832: Coagulation factor VIII/Von Willebrand Factor Human

Coagulation factor VIII/Von Willebrand Factor Human is a multimeric glycoproteins used to treat or prevent bleeding episodes in people with Hemophilia A and Von Willebrand Disease.

UNSPSC 51131832 Coagulation factor VIII/Von Willebrand Factor Human is a Commodity code that state and local governments rarely procure directly; the recent opportunities posted under this code show minimal alignment with the nominal pharmaceutical ingredient scope. The single relevant solicitation, West Texas Centers for Mental Health and Mental Retardation's RFP for prescription and pharmacy services (RX1001, due August 21, 2026), encompasses broader pharmaceutical dispensing, inventory, and consultation services for over 7,000 individuals across 35 sites in 23 counties rather than specific clotting-factor procurement. The remaining opportunities tagged to this code address unrelated services: emergency-medicine software (Collier County), long-term-care pharmacy distribution (Dane County), aquatic-center operations (Palm Bay), pharmacy-benefits network qualifications (District of Columbia), drug-deactivation systems (Seminole County), BLS/ALS supply vending (Tucson), and forensic drug-reference standards (Pinellas County). This code shows no active state or local market for coagulation-factor products themselves; procurement activity under this designation appears to reflect administrative miscoding rather than genuine demand for Factor VIII or Von Willebrand Factor concentrates.

The issuing bodies in recent postings span counties, cities, and regional health authorities across Florida, Texas, Oregon, Wisconsin, Kentucky, California, and Arizona, with no pattern indicating repeat buyers or sustained procurement under the coagulation-factor code. West Texas Centers for Mental Health, the closest match to pharmaceutical services, operates on a tiered markup structure with a 37% Medicaid rate and requires Texas State Board of Pharmacy licensure, Texas and DEA registrations, and Medicare/Medicaid provider status in good standing. Geographic activity is scattered across the South, Southwest, and West with no concentration. The code does not appear to represent a viable pursuit pathway for clotting-factor manufacturers or distributors seeking state and local contracts; vendors should monitor higher-tier pharmaceutical or medical-supply family codes instead for aligned opportunities in this segment.